Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Tanya R Riley"'
Publikováno v:
American Journal of Health-System Pharmacy. 80:652-662
Purpose This review aims to provide an update on current pharmacological agents for the management of generalized myasthenia gravis (MG). Summary MG is an autoimmune disease characterized by impaired neuromuscular transmission and muscle weakness. Mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a597f44b1d93c0f8074c20bb9e472a2d
https://doi.org/10.1093/ajhp/zxad035
https://doi.org/10.1093/ajhp/zxad035
Autor:
Treavor T. Riley, Tanya R. Riley
Publikováno v:
Journal of Blood Medicine. 10:307-311
Sickle cell disease (SCD) is one of the most common inherited blood disorders globally. It is a grouping of autosomal recessive genetic disorders identified by a genetic mutation that replaces glutamic acid with valine at the sixth amino acid on the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d456ef3358a04964a1ed75f3899795e2
https://doi.org/10.2147/jbm.s191423
https://doi.org/10.2147/jbm.s191423
Publikováno v:
Journal of Pharmacy Practice. 30:214-218
Objective: To determine the incidence and severity of bleeding events requiring hospitalization among patients with atrial fibrillation (AF) receiving anticoagulants (dabigatran or warfarin) or antiplatelet agents (eg, aspirin and clopidogrel). Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dc9a902334889934c6023af0d5247ec
https://doi.org/10.1177/0897190016630408
https://doi.org/10.1177/0897190016630408
Publikováno v:
PT : a peer-reviewed journal for formulary management. 43(7)
This article reviews the clinical data concerning the uses of hydroxyurea, L-glutamine, and crizanlizumab in treating pain crises associated with sickle cell disease.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9c6460a5b81cdd1707ff9b8927be1b97
https://pubmed.ncbi.nlm.nih.gov/30013299
https://pubmed.ncbi.nlm.nih.gov/30013299
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 74(2)
Purpose The available clinical data on target-specific oral anticoagulant (TSOAC) reversal agents that are currently in development or have been approved by the Food and Drug Administration (FDA) are reviewed. Summary The development of TSOACs such a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::215a36bd600cef1519928856ff1dd9b8
https://pubmed.ncbi.nlm.nih.gov/27895055
https://pubmed.ncbi.nlm.nih.gov/27895055